Page 152 - CW E-Magazine (15-10-2024)

Pharmaceuticals Pharmaceuticals

SUSTAINABILITY REPORT ‘ REACHING LOW-INCOME MARKETS
Piramal Pharma building resilience for a sustainable Dr. Reddy’s, Hetero sign voluntary licenses with

tomorrow’ Gilead for HIV drug

Piramal Pharma Limited (PPL) has factor authentication for O365 and en- Hyderabad-based Hetero Drugs and been at the forefront of the global fi ght
released its third independent annual hanced data protection protocols for Dr. Reddy’s Laboratories (DRL) have against HIV/AIDS, pioneering afforda-
Sustainability Report for the fi nancial North American sites, as well as con- signed a non-exclusive, royalty-free volun- ble, life-saving treatments where the
year 2023-24, under the theme ‘Build- ducting Vulnerability Assessment and tary licensing agreement with Gilead need is greatest. With over 30 combina-
ing Resilience Today for a Sustainable Penetration Testing (VAPT) scans. PPL Sciences Ireland UC to manufacture and tions addressing nearly 40 per cent of the
Tomorrow.’ continues to invest in a diverse, inclu- distribute lenacapavir, a breakthrough global HIV/AIDS population, we take
sive, and accessible workplace, with HIV treatment drug, in 120 primarily immense pride in the positive impact
The report highlights PPL’s ap- women representing 17.3% of its global low- and lower-middle-income coun- our efforts have made so far. We will fur-
proach across four key strategic pil- workforce, including 72% of new tries (LMICs), including India. ther bring quick access to lenacapavir in
lars: Responsible Operations, Business campus hires. Through comprehensive Africa, India, and other LMICs, where
Resilience, Customer Centricity, and progress toward a more sustainable safety and health programs, PPL main- Lenacapavir is a USFDA-approved post-exposure treatment of HIV. The we’ve been a cornerstone of HIV/AIDS
Quality & Excellence. These pillars future,” said Ms. Nandini Piramal, tains a Lost Time Injury Rate (LTIR) drug indicated for the treatment of collaboration with Gilead will help us care,” said Mr. Vamsi Krishna Bandi,
underscore the company’s focus on Chairperson, PPL, said. below 0.2 per 200,000 person-days. human immunodefi ciency virus type make this latest treatment option availa- Managing Director, Hetero Group of
climate action, supply chain responsibi- 1 (HIV-1) infection in heavily treat- ble to patients in 120 primarily low- and Companies.
lity, innovation, and operational excel- Responsible Operations PPL rolled out a sustainability ment-experienced adults with multi- lower-middle-income countries, includ-
lence, all while ensuring the well-being PPL has made substantial progress e-learning module for employees, and drug-resistant HIV-1 infection, failing ing India. Many of these countries have Earlier this month, Gilead announced
of its employees and the communities in its energy effi ciency efforts, with a approximately 200 senior leaders in their current antiretroviral regimen due a very high disease burden of HIV. This promising results from a pivotal Phase
it serves. 29% increase in renewable energy con- India participated in Diversity, Inclusion, to resistance, intolerance, or safety con- is an important endeavour in our journey 3 clinical trial. The interim analysis
sumption. The company is committed Belonging, and Accessibility (DIBA) siderations. Additionally, lenacapavir to create impact on 1.5-billion patients demonstrated that lenacapavir reduced
PPL’s comprehensive strategy inte- to reducing absolute Scope 1 and 2 workshops. is currently under investigation for the by 2030,” said Mr. Deepak Sapra, CEO, HIV infections by 96% compared to the
grates sustainability principles across GHG emissions by 42% and Scope 3 prevention of HIV (PrEP), which is yet API and Services, DRL, said. background HIV incidence. This high-
all operations and decision-making, emissions by 25% by FY 2030, using Quality & Excellence to be approved globally. Gilead Sciences lights the transformative potential of lena-
focusing on 12 key areas and 28 material FY 2022 as the base year as validated In FY 2024, PPL successfully com- fi rst launched lenacapavir under the Broadened access capavir as a long-acting treatment and
topics, supported by over 50 specifi c by the Science Based Targets initiative pleted 341 regulatory inspections, in- brand name Sunlenca in the US and Gilead’s price for lenacapavir in prevention option. Further, lenacapavir
time-bound targets. This framework (SBTi). cluding 44 by the US FDA, with no European markets in 2022. It is a fi rst- high-income countries is $42,250 annu- is also being studied as a long-acting
ensures PPL to effectively manage its critical observations. Additionally, in-class HIV-1 capsid inhibitor. ally, but researchers estimate Indian sup- HIV prevention drug in ongoing clinical
sustainability responsibilities and drive Energy audits were completed at close to 1,746 customer audits were pliers could produce the drug for as little trials. This drug’s long-acting version
meaningful impact across its global all sites, identifying opportunities for conducted across global operations. “Lenacapavir marks an important as $100 per person per year, with further can be administered every six months
operations and value chain. emission reductions through renew- Automation has been a key driver milestone for Dr. Reddy’s in patient reductions possible as demand increases. via a subcutaneous injection, following
able energy sourcing (13%), low-carbon of effi ciency, with 70% of six major access and affordability for pre- and “For over three decades, Hetero has an initial oral loading dose.
“Our latest Sustainability Report fuel switching (21%), and energy operational excellence KPIs automated
not only highlights the milestones effi ciency measures (7%). In both across 11 sites. The company intro- CCI approves Mankind Pharma’s acquisition of
we’ve achieved but also demonstrates India and the UK, 80% of non-hazardous duced 23 new robotic process auto-
our capability to adapt to evolving waste was recycled and the company mation (RPA) processes, bringing the Bharat Serums
global standards. By revising our planted 2,440 saplings and implemen- total to 54 live processes.
Scope 1 and 2 GHG emissions and ted 15 water-saving micro-projects in The Competition Commission as a leader in the Indian women’s health
energy consumption for FY 2023, we India, resulting in 114-kl of water Customer Centricity of India (CCI) has cleared Mankind and fertility drug market. Mankind is
have signifi cantly improved data accu- savings per day. PPL achieved a customer satisfac- Pharma’s acquisition of Bharat Serums engaged in developing and marketing a
racy, enabling us to assess and manage tion score of 85% for its Contract and Vaccines in a Rs. 13,630-crore deal. diverse range of pharmaceutical fi nished
our environmental footprint. Looking Business Resilience Development and Manufacturing dosage formulations, as well as several
ahead, we remain committed to driv- PPL introduced a Sustainable Pro- Organization (CDMO) business and 87% Mankind had announced in July consumer healthcare products. Bharat
ing sustainable growth; reinforcing our curement Policy and revised its Supplier for its Consumer Healthcare (CHG) busi- that it would acquire private equity Serums and Vaccines is engaged in manu-
core purpose of ‘Doing Well and Doing Code of Conduct, ensuring sustaina- ness. The Net Promoter Scores (NPS) fi rm Advent International’s 100% stake facturing and marketing of fi nished
Good,’ while strengthening our focus ble practices across its supply chain. were 57 and 65 for the CDMO and CHG in Bharat Serums and Vaccines. The dosage formulations and active pharma-
on making meaningful, measurable Initiatives included the rollout of multi- businesses, respectively. move is expected to position Mankind ceutical ingredients.

152 Chemical Weekly October 15, 2024 Chemical Weekly October 15, 2024 153

Contents Index to Advertisers Index to Products Advertised